Visualization of transepidermal invasion of fluorescent HIV and development of the new HIV entry inhibitor

很明显，服用马拉维克（MVC）的志愿者表皮的朗格汉斯细胞（LCs）对HIV感染具有很强的抵抗力，这表明MVC；作为艾滋病治疗药物开发的药物已被证明是一种有用的口服微量药物。此外，单核细胞源性LCs体外HIV感染实验表明，EFdA和MVC对HIV感染有较好的抑制作用，EFdA可作为微旁剂实际应用。

It became clear that Langerhans cells (LCs) in the epidermis of volunteer, who took Maraviroc (MVC), had very strong resistance for HIV infection, suggesting that MVC; the agent developed as an AIDS therapeutic drug has been demonstrated as a useful oral micro beside. In addition, in the in vitro HIV infection experiment with monocyte-derived LCs, it was suggested that EFdA and MVC had a superior suppressant effect against HIV infection, and that EFdA can be practically used as micro beside.